Alpha 2.0
Login Register
» Authors » Rodney Sinclair

Rodney Sinclair

Explore the profile of Rodney Sinclair including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 220
Citations 2684
Followers 0
Related Specialties
Dermatology
General Medicine
Public Health
Top 10 Co-Authors
Nekma Meah
Dmitri Wall
Brett King
Jerry Shapiro
Laita Bokhari
Antonella Tosti
Sergio Vano-Galvan
Bevin Bhoyrul
Samantha Eisman
Lidia Rudnicka
Published In
Australas J Dermatol
J Am Acad Dermatol
Int J Dermatol
Clin Exp Dermatol
Dermatol Ther
Affiliations
Soon will be listed here.
Recent Articles
21.
Dissecting cellulitis of the scalp in a paediatric male
Thomas M, Yii V, Sinclair R
Australas J Dermatol . 2024 Jun; 65(8):657-659. PMID: 38922844
No abstract available.
22.
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al.
Am J Clin Dermatol . 2024 May; 25(4):689. PMID: 38789821
No abstract available.
23.
Health-related quality of life of adult and adolescent patients living with alopecia areata in Australia
Sinclair R, Eisman S, Lee C, Hitschfeld M, Witcombe D, da Fonseca Pereira C
Australas J Dermatol . 2024 May; 65(5):451-461. PMID: 38764404
Introduction: To understand the experiences of adolescent and adult patients living with alopecia areata (AA) in Australia regarding symptom severity and the impact on psychosocial well-being and work/classroom productivity. Materials...
24.
Porokeratosis
Awad A, Nirenberg A, Colla T, Sinclair R
Clin Exp Dermatol . 2024 May; 49(12):1733-1734. PMID: 38747355
No abstract available.
25.
Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome
Moussa A, Darchini-Maragheh E, Wall D, Meah N, Sinclair R
J Am Acad Dermatol . 2024 Apr; 91(2):346-348. PMID: 38588822
No abstract available.
26.
Role of systemic minoxidil in the treatment of alopecia areata: A scoping review to direct future research
Darchini-Maragheh E, Rees H, Moussa A, Bokhari L, Jones L, Sinclair R
J Am Acad Dermatol . 2024 Feb; 90(6):1304-1306. PMID: 38423467
No abstract available.
27.
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity
Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, et al.
JAMA Dermatol . 2024 Feb; 160(3):341-350. PMID: 38324292
Importance: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. Objective: To explore factors associated with AA...
28.
Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib
Tang G, Triwongwaranat D, Sinclair R, Joseph S, Eisman S, Rathnayake D, et al.
Clin Exp Dermatol . 2024 Jan; 49(8):875-878. PMID: 38270233
Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical...
29.
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al.
Am J Clin Dermatol . 2024 Jan; 25(2):299-314. PMID: 38263353
Background: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12...
30.
Comment on Xia et al "Outcome Measures for Alopecia Areata"
Darchini-Maragheh E, Sinclair R
J Invest Dermatol . 2023 Nov; 144(5):1165-1166. PMID: 38008247
No abstract available.